Multiparametric Analysis of Longitudinal Quantitative MRI Data to Identify Distinct Tumor Habitats in Preclinical Models of Breast Cancer

This study identifies physiological tumor habitats from quantitative magnetic resonance imaging (MRI) data and evaluates their alterations in response to therapy. Two models of breast cancer (BT-474 and MDA-MB-231) were imaged longitudinally with diffusion-weighted MRI and dynamic contrast-enhanced MRI to quantify tumor cellularity and vascularity, respectively, during treatment with trastuzumab or albumin-bound paclitaxel. Tumors were stained for anti-CD31, anti-Ki-67, and H&E. Imaging and histology data were clustered to identify tumor habitats and percent tumor volume (MRI) or area (histology) of each habitat was quantified. Histological habitats were correlated with MRI habitats. Clustering of both the MRI and histology data yielded three clusters: high-vascularity high-cellularity (HV-HC), low-vascularity high-cellularity (LV-HC), and low-vascularity low-cellularity (LV-LC). At day 4, BT-474 tumors treated with trastuzumab showed a decrease in LV-HC (p = 0.03) and increase in HV-HC (p = 0.03) percent tumor volume compared to control. MDA-MB-231 tumors treated with low-dose albumin-bound paclitaxel showed a longitudinal decrease in LV-HC percent tumor volume at day 3 (p = 0.01). Positive correlations were found between histological and imaging-derived habitats: HV-HC (BT-474: p = 0.03), LV-HC (MDA-MB-231: p = 0.04), LV-LC (BT-474: p = 0.04; MDA-MB-231: p < 0.01). Physiologically distinct tumor habitats associated with therapeutic response were identified with MRI and histology data in preclinical models of breast cancer.

[1]  Baishali Chaudhury,et al.  Heterogeneity in intratumoral regions with rapid gadolinium washout correlates with estrogen receptor status and nodal metastasis , 2015, Journal of magnetic resonance imaging : JMRI.

[2]  N. Otsu.  A threshold selection method from gray level histograms , 1979 .

[3]  J. Gore,et al.  An Approach to Breast Cancer Diagnosis via PET Imaging of Microcalcifications Using 18F-NaF , 2014, The Journal of Nuclear Medicine.

[4]  Xin Li,et al.  Dynamic-contrast-enhanced-MRI with extravasating contrast reagent: rat cerebral glioma blood volume determination. , 2010, Journal of magnetic resonance.

[5]  P. Choyke,et al.  Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. , 2009, Neoplasia.

[6]  A. Madabhushi,et al.  Computerized image analysis for identifying triple-negative breast cancers and differentiating them from other molecular subtypes of breast cancer on dynamic contrast-enhanced MR images: a feasibility study. , 2014, Radiology.

[7]  Robert J. Gillies,et al.  Predicting Ki67% expression from DCE-MR images of breast tumors using textural kinetic features in tumor habitats , 2016, SPIE Medical Imaging.

[8]  M. Bentires-Alj,et al.  Breast Tumor Heterogeneity: Source of Fitness, Hurdle for Therapy. , 2015, Molecular cell.

[9]  Meiyappan Solaiyappan,et al.  Collagen fibers mediate MRI-detected water diffusion and anisotropy in breast cancers , 2016, Neoplasia.

[10]  Gloria Menegaz,et al.  DCE-MRI and DWI Integration for Breast Lesions Assessment and Heterogeneity Quantification , 2012, Int. J. Biomed. Imaging.

[11]  Miklós Espák,et al.  Cluster analysis of quantitative parametric maps from DCE-MRI: application in evaluating heterogeneity of tumor response to antiangiogenic treatment. , 2015, Magnetic resonance imaging.

[12]  K. Polyak,et al.  Tumorigenesis: it takes a village , 2015, Nature Reviews Cancer.

[13]  Thomas E Yankeelov,et al.  Comparisons of the efficacy of a Jak1/2 inhibitor (AZD1480) with a VEGF signaling inhibitor (cediranib) and sham treatments in mouse tumors using DCE-MRI, DW-MRI, and histology. , 2012, Neoplasia.

[14]  Bernhard Schölkopf,et al.  A Novel Unsupervised Segmentation Approach Quantifies Tumor Tissue Populations Using Multiparametric MRI: First Results with Histological Validation , 2016, Molecular Imaging and Biology.

[15]  Ruijiang Li,et al.  Intratumor partitioning and texture analysis of dynamic contrast‐enhanced (DCE)‐MRI identifies relevant tumor subregions to predict pathological response of breast cancer to neoadjuvant chemotherapy , 2016, Journal of magnetic resonance imaging : JMRI.

[16]  Baris Turkbey,et al.  Delineation of Tumor Habitats based on Dynamic Contrast Enhanced MRI , 2017, Scientific Reports.

[17]  E. Winer,et al.  Personalisation of Radiotherapy for Breast Cancer , 2016 .

[18]  F. Esteva,et al.  Her2-positive breast cancer: herceptin and beyond. , 2008, European journal of cancer.

[19]  Arend Hintze,et al.  Data Preprocessing , 2017, Encyclopedia of Machine Learning and Data Mining.

[20]  Jason A Koutcher,et al.  Mapping Tumor Hypoxia In Vivo Using Pattern Recognition of Dynamic Contrast-enhanced MRI Data. , 2012, Translational oncology.

[21]  Xia Li,et al.  DCE‐MRI analysis methods for predicting the response of breast cancer to neoadjuvant chemotherapy: Pilot study findings , 2014, Magnetic resonance in medicine.

[22]  R. Gatenby,et al.  Multiparameter MRI Predictors of Long-Term Survival in Glioblastoma Multiforme , 2019, Tomography.

[23]  Maria Bernathova,et al.  Diffusion‐weighted MRI of breast lesions: a prospective clinical investigation of the quantitative imaging biomarker characteristics of reproducibility, repeatability, and diagnostic accuracy , 2016, NMR in biomedicine.

[24]  C. Maley,et al.  Cancer is a disease of clonal evolution within the body1–3. This has profound clinical implications for neoplastic progression, cancer prevention and cancer therapy. Although the idea of cancer as an evolutionary problem , 2006 .

[25]  F. Sato,et al.  Genomic tumor evolution of breast cancer , 2015, Breast Cancer.

[26]  Erich P Huang,et al.  Quantitative MRI radiomics in the prediction of molecular classifications of breast cancer subtypes in the TCGA/TCIA data set , 2016, npj Breast Cancer.

[27]  Wei Huang,et al.  Early Prediction and Evaluation of Breast Cancer Response to Neoadjuvant Chemotherapy Using Quantitative DCE-MRI1 , 2016, Translational oncology.

[28]  Thomas E. Yankeelov,et al.  Characterizing Trastuzumab-Induced Alterations in Intratumoral Heterogeneity with Quantitative Imaging and Immunohistochemistry in HER2+ Breast Cancer , 2018, Neoplasia.

[29]  Izhak Haviv,et al.  Co-evolution of tumor cells and their microenvironment. , 2009, Trends in genetics : TIG.

[30]  T. Yankeelov,et al.  Trastuzumab improves tumor perfusion and vascular delivery of cytotoxic therapy in a murine model of HER2+ breast cancer: preliminary results , 2016, Breast Cancer Research and Treatment.

[31]  A. Padhani,et al.  Reproducibility of dynamic contrast‐enhanced MRI in human muscle and tumours: comparison of quantitative and semi‐quantitative analysis , 2002, NMR in biomedicine.

[32]  M. Dewhirst,et al.  Her2/neu signaling blockade improves tumor oxygenation in a multifactorial fashion in Her2/neu+ tumors , 2008, Cancer Chemotherapy and Pharmacology.

[33]  Carlo C. Maley,et al.  An ecological measure of immune-cancer colocalization as a prognostic factor for breast cancer , 2015, Breast Cancer Research.

[34]  Massimo Filippi,et al.  Diffusion-Weighted MRI , 2003 .

[35]  Wiro J. Niessen,et al.  Facilitating Tumor Functional Assessment by Spatially Relating 3D Tumor Histology and In Vivo MRI: Image Registration Approach , 2011, PloS one.

[36]  Juan J. Martinez,et al.  Spatial Habitat Features Derived from Multiparametric Magnetic Resonance Imaging Data Are Associated with Molecular Subtype and 12-Month Survival Status in Glioblastoma Multiforme , 2015, PloS one.

[37]  Xiaoyuan Chen,et al.  DCE-MRI-Derived Parameters in Evaluating Abraxane-Induced Early Vascular Response and the Effectiveness of Its Synergistic Interaction with Cisplatin , 2016, PloS one.

[38]  R. Danesi,et al.  The pharmacological bases of the antiangiogenic activity of paclitaxel , 2013, Angiogenesis.

[39]  E. Rofstad,et al.  Dynamic contrast‐enhanced‐MRI of tumor hypoxia , 2012, Magnetic resonance in medicine.

[40]  Julian C. Matthews,et al.  Data‐driven mapping of hypoxia‐related tumor heterogeneity using DCE‐MRI and OE‐MRI , 2017, Magnetic resonance in medicine.

[41]  M. Knopp,et al.  Estimating kinetic parameters from dynamic contrast‐enhanced t1‐weighted MRI of a diffusable tracer: Standardized quantities and symbols , 1999, Journal of magnetic resonance imaging : JMRI.

[42]  T. Yankeelov,et al.  Evaluating treatment response using DW-MRI and DCE-MRI in trastuzumab responsive and resistant HER2-overexpressing human breast cancer xenografts , 2014, Translational oncology.

[43]  Alex J Walsh,et al.  In vivo hyperspectral imaging of microvessel response to trastuzumab treatment in breast cancer xenografts. , 2014, Biomedical optics express.

[44]  Douglas Hanahan,et al.  Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment Prospects and Obstacles for Therapeutic Targeting of Function-enabling Stromal Cell Types , 2022 .

[45]  M. Junttila,et al.  Influence of tumour micro-environment heterogeneity on therapeutic response , 2013, Nature.

[46]  Ruijiang Li,et al.  Intratumoral Spatial Heterogeneity at Perfusion MR Imaging Predicts Recurrence-free Survival in Locally Advanced Breast Cancer Treated with Neoadjuvant Chemotherapy. , 2018, Radiology.

[47]  Lihua Li,et al.  Radiomic analysis reveals DCE-MRI features for prediction of molecular subtypes of breast cancer , 2017, PloS one.

[48]  Eun-Kyung Kim,et al.  Triple-negative invasive breast cancer on dynamic contrast-enhanced and diffusion-weighted MR imaging: comparison with other breast cancer subtypes , 2012, European Radiology.

[49]  R. Gillies,et al.  Multiparametric MRI and co-registered histology identify tumor habitats in breast cancer mouse models. , 2019, Cancer research.

[50]  Thomas E Yankeelov,et al.  Dynamic Contrast Enhanced Magnetic Resonance Imaging in Oncology: Theory, Data Acquisition, Analysis, and Examples. , 2007, Current medical imaging reviews.

[51]  G. Parker,et al.  Imaging Intratumor Heterogeneity: Role in Therapy Response, Resistance, and Clinical Outcome , 2014, Clinical Cancer Research.

[52]  Steinar Lundgren,et al.  Dynamic contrast‐enhanced MRI texture analysis for pretreatment prediction of clinical and pathological response to neoadjuvant chemotherapy in patients with locally advanced breast cancer , 2014, NMR in biomedicine.

[53]  R. Gillies,et al.  Radiologically defined ecological dynamics and clinical outcomes in glioblastoma multiforme: preliminary results. , 2014, Translational oncology.

[54]  T. Yankeelov,et al.  Repeatability, reproducibility, and accuracy of quantitative mri of the breast in the community radiology setting , 2018, Journal of magnetic resonance imaging : JMRI.

[55]  N. van Bruggen,et al.  Quantification of viable tumor microvascular characteristics by multispectral analysis , 2008, Magnetic resonance in medicine.

[56]  J. Gore,et al.  A quantitative comparison of the influence of individual versus population‐derived vascular input functions on dynamic contrast enhanced‐MRI in small animals , 2012, Magnetic resonance in medicine.

[57]  Carlo C. Maley,et al.  Clonal evolution in cancer , 2012, Nature.

[58]  J. O'Connor,et al.  Cancer heterogeneity and imaging. , 2017, Seminars in cell & developmental biology.

[59]  Lei Xu,et al.  Tumour biology: Herceptin acts as an anti-angiogenic cocktail , 2002, Nature.

[60]  C. Rueden,et al.  Metadata matters: access to image data in the real world , 2010, The Journal of cell biology.

[61]  C. Sotak,et al.  Multispectral tissue characterization in a RIF‐1 tumor model: Monitoring the ADC and T2 responses to single‐dose radiotherapy. Part II , 2007, Magnetic resonance in medicine.

[62]  D. Yardley.  nab-Paclitaxel mechanisms of action and delivery. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[63]  R. Gillies,et al.  Quantitative imaging in cancer evolution and ecology. , 2013, Radiology.

[64]  Charles Swanton,et al.  Clinical management of breast cancer heterogeneity , 2015, Nature Reviews Clinical Oncology.

[65]  G. Viale,et al.  The microtubule-affecting drug paclitaxel has antiangiogenic activity. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[66]  Chengyue Wu,et al.  Quantitative analysis of vascular properties derived from ultrafast DCE‐MRI to discriminate malignant and benign breast tumors , 2018, Magnetic resonance in medicine.

[67]  R. Yelensky,et al.  Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. , 2014, Cancer discovery.

[68]  S. Kety.  The theory and applications of the exchange of inert gas at the lungs and tissues. , 1951, Pharmacological reviews.

[69]  Robert Tibshirani,et al.  Estimating the number of clusters in a data set via the gap statistic , 2000 .

[70]  N. Just,et al.  Improving tumour heterogeneity MRI assessment with histograms , 2014, British Journal of Cancer.

[71]  Thomas E Yankeelov,et al.  DCE‐ and DW‐MRI as early imaging biomarkers of treatment response in a preclinical model of triple negative breast cancer , 2017, NMR in biomedicine.

[72]  K. Polyak,et al.  Tumor heterogeneity: causes and consequences. , 2010, Biochimica et biophysica acta.

[73]  M. Giger,et al.  Volumetric texture analysis of breast lesions on contrast‐enhanced magnetic resonance images , 2007, Magnetic resonance in medicine.

[74]  R. Gillies,et al.  Habitats in DCE-MRI to Predict Clinically Significant Prostate Cancers , 2019, Tomography.

[75]  N. Hylton,et al.  MRI methods for evaluating the effects of tyrosine kinase inhibitor administration used to enhance chemotherapy efficiency in a breast tumor xenograft model , 2009, Journal of magnetic resonance imaging : JMRI.

[76]  L. Infante,et al.  Hierarchical Clustering , 2020, International Encyclopedia of Statistical Science.

[77]  Bing Ma,et al.  Multi-Site Clinical Evaluation of DW-MRI as a Treatment Response Metric for Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy , 2015, PloS one.

[78]  Savannah C. Partridge,et al.  DWI in the Assessment of Breast Lesions , 2017, Topics in magnetic resonance imaging : TMRI.

[79]  Robert J. Gillies,et al.  Association of multiparametric MRI quantitative imaging features with prostate cancer gene expression in MRI-targeted prostate biopsies , 2016, Oncotarget.

[80]  T. Yankeelov,et al.  Quantitative [18F]FMISO PET Imaging Shows Reduction of Hypoxia Following Trastuzumab in a Murine Model of HER2+ Breast Cancer , 2017, Molecular Imaging and Biology.